Almasri M,Ismaiel A,Gavris I,Leucuta DC,Gavris MM,Nicoara SD .2024 .Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis. Eye, 38 : 3222-3230.
Alnagdy A,Eissa AM,El-Kannishy A .2019 .Topical NSAIDs in prevention of postcataract macular edema. Front Ophthalmol. Ocular. Imag., 13 : 2317-2325.
Alnagdy AA,Abouelkheir HY,El-Khouly SE,Tarshouby SM .2018 .Impact of topical nonsteroidal anti-inflammatory drugs in prevention of macular edema following cataract surgery in diabetic patients. Inter J. Ophthalmol., 11(4) : 616-622.
Bunjo LJ,Bacchi S,Pietris J,Chan WO .2024 .Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review. Survey Ophthalmol, 69(4) : 606-621.
Carricondo PC,Abalem MF,Machado CG,KaraJunior N CG .2015 .Prophylaxis and treatment of cystoids macular edema after cataract surgery. Cat. Refr. Surg., 74 : 51-3.
Chastain JE,Sanders ME,Curtis MA,Chemuturi NV,Gadd ME,Kapin MA,Markwardt KL,Dahlin DC .2016 .Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp. Eye. Res., 145 : 58-67.
Dick BH,Schultz T .2017 .Cystoid macular edema after femtosecond laser-assisted versus phacoemulsification cataract surgery. J. Cataract. Refract. Surg., 42(6) : 947-8.
Donnenfeld ED,Perry HD,Wittpenn JR,Solomon R,Nattis A,Chou T .2006 .Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J. Catar. Refract. Surg., 32(9) : 1474-1482.
El Gharbawy SA,Darwish EA,Abu Eleinen KG,Osman MH .2019 .Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes. Europ. J. Ophthalmol., 29(4) : 453-457.
Ellakwa AF,Badawy NM .2020 .Evaluation of nepafenac eye drops in prevention of macular edema following cataract surgery. Menouf, 33(2) : 604-610.
Endo N,Kato S,Haruyama K,Shoji M,Kitano S M .2010 .Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta. Ophthalmolog, 88(8) : 896-900.
Giarmoukakis AK,Blazaki SV,Bontzos GC,Plaka AD,Seliniotakis KN,Ioannidi LD,Tsilimbaris MK .2020 .Efficacy of topical nepafenac 0.3% in the management of postoperative cystoid macular edema. Ther. Clinic Risk Manag., 16 : 1067-1074.
Hariprasad SM,Callanan D,Gainey S,He YG,Warren K YG,Ocul YG .2007 .Cystoid and diabetic macular edema treated with nepafenac 0.1%. , 23(6) : 585-590.
Heier JS,Topping TM,Baumann W,Dirks MS,Chern S MS .2000 .Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. , 107(11) : 2034-2038.
Iftikhar M,Dun C,Schein OD,Lum F,Woreta F F .2023 .Cystoid macular edema after cataract surgery in the United States: IRIS® registry (Intelligent Research in Sight) analysis. , 130(10) : 1005-1014.
Kelkar A,Kelkar J,Mehta H,Amoaku W H .2018 .Cataract surgery in diabetes mellitus: A systematic review. Indian J. Ophthalmol., 66(10) : 1401-1410.
Kessel L,Tendal B,Jørgensen KJ,Erngaard D,Flesner P,Andresen JL,Hjortdal J .2014 .Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmol., 121(10) : 1915-1924.
Kim SJ,Patel SN,Sternberg P .2016 .Routine use of nonsteroidal anti-inflammatory drugs with corticosteroids in cataract surgery: beneficial or redundant?. Ophthalmol, 123(3) : 444-446.
Kiziltoprak H,Tekin K,Inanc M,Goker YS M .2019 .Cataract in diabetes mellitus. World J. Diabetes, 10(3) : 140.
Kusbeci T,Eryigit L,Yavas G,Inan UU G .2012 .Evaluation of cystoid macular edema using optical coherence tomography and fundus fluorescein angiography after uncomplicated phacoemulsification surgery. Curr. Eye Res., 37(4) : 327-333.
Kwon SI,Hwang DJ,Seo JY,Park IW .2011 .Evaluation of changes of macular thickness in diabetic retinopathy after cataract surgery. Korean J. Ophthalmol., 25(4) : 238-242.
Lashari MA,Memon SUH,Maree GK,Channa S,Das N,Hussain A .2024 .Incidence and risk factors of macular edema after phacoemulsification in southern Pakistan. , 20(1) : 40-44.
Lim BX,Lim CHL,Lim DK,Evans JR,Bunce C,Wormald R C .2016 .Prophylactic non-steroidal antiinflammatory drugs for the prevention of macular oedema after cataract surgery. Cochrane Database Syst. Rev, 11(11) : 1-159.
Loewenstein A,Zur D A .2010 .Postsurgical cystoid macular edema. Dev. Opthalmol, 4 : 148-159.
Manaviat MR,Oveisi N,Zare-Bidoki A .2015 .Accelerated bilateral cataract formation as a first manifestation of diabetes mellitus. Prague. Medi. Report., 114(4) : 258-262.
McCafferty S,Harris A,Kew C,Kassm T,Lane L,Levine J,Raven M .2017 .Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC, 17 : 1-7.
McGhee CN,Dean S,Danesh-Meyer H .2002 .Locally administered ocular corticosteroids: benefits and risks. , 25 : 33-55.
Mentes J,Erakgun T,Afrashi F,Kerci G F .2003 .Incidence of cystoid macular edema after uncomplicated phacoemulsification. , 217(6) : 408-412.
Mozaffarieh M,Heinzl H,Sacu S,Wedrich A .2005 .Clinical outcomes of phacoemulsification cataract surgery in diabetes patients: Visual function (VF-14), visual acuity and patient satisfaction. Acta. Ophthalmolog, 83(2) : 176-183.
Nanda AK,Kanungo S,Swain A .2022 .A comparison of efficacy of nepafenac 0.1% with nepafenac 0.3% drops for the management of post-operative inflammation and CME in uneventful phacoemulsification. Intern. J. Resear. Review, 9(3) : 228-236.
O'Brien TP .2005 .Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr. Med. Res. Opin., 21(7) : 1131-1137.
Pollack A,Staurenghi G,Sager D,Mukesh B,Reiser H,Singh RP H .2017 .Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Br. J. Ophthalmol., 101(4) : 423-427.
Ray S and D'Amico DJ .2002 .Pseudophakic cystoid macular edema. Semin Ophthalmol, 17(3-4) : 167-180.
Sadiq SA,Sleep T,Amoaku WMK .1999 .The visual results and changes in retinopathy in diabetic patients following cataract surgery. Europ. J. Ophthalmol., 9(1) : 14-20.
Sarfraz MH,Haq RIU,Mehboob MA .2017 .Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy. Pak. J. Med. Sci., 33(1) : 210-214.
Shelsta HN,Jampol LM .2011 .Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina., 31(1) : 4-12.
Singh RP,Lehmann R,Martel J,Jong K,Pollack A,Tsorbatzoglou A,Staurenghi G,Cervantes GCC,Alpern L,Modi S,Svoboda L S .2017 .Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies. , 124(6) : 776-785.
Soliman W,Sander B,Jørgensen TM B .2007 .Enhanced optical coherence patterns of diabetic macular oedema and their correlation with the pathophysiology. Acta. Ophthalmol, 85(6) : 613-617.
Tzelikis PF,Morato CS,Neves NT,Hida WT,Alves MR .2018 .Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification. J. Catar. Refrac. Surg., 44(4) : 440-446.
Ullah W,Irfan M,Khan SAR,Ghalib A,Khalil ZU .2021 .Role of topical nepafenac in preventing increase in macular thickness after phacoemulsification. J. Postgrad. Med, 34(4) : 253-8.
Walters T,Raizman M,Ernest P,Gayton J,Lehmann R .2007 .In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J. Catar. Refract. Surg., 33(9) : 1539-1545.
Yang J,Cai L,Sun Z,Ye H,Fan Q,Zhang K,Lu W,Lu Y .2017 .Risk factors for and diagnosis of pseudophakic cystoid macular edema after cataract surgery in diabetic patients. J. Cataract. Refract. Surg., 43(2) : 207-214.
Zur D and Loewenstein A .2017 .Postsurgical cystoid macular edema. Dev. Opthalmol, 58 : 178-190.